Capped vials are being pictured during filling and packaging tests for the large-scale production and supply of the University of Oxfords COVID-19 vaccine candidate, AZD1222 VINCENZO PINTO/AFP via Getty Images
For the third consecutive Monday, a drugmaker said its coronavirus vaccine candidate was successful in late-stage studies.
AstraZeneca and the University of Oxford said preliminary results showed that their two-dose vaccine was effective at preventing COVID-19.
AstraZeneca's news followed similar announcements from Pfizer and Moderna, both of which said their experimental COVID-19 shots appeared to be 95% effective at preventing COVID-19.
A CB Insights report out Wednesday analyzed funding for healthcare startups through November 17 to better predict how the industry will end the final quarter of 2020.
Funding slowed in the first half of the quarter for all healthcare startups, and the projections for the remainder of the year were similarly lower compared to the record-breaking second and third quarters this year.
A volunteer receives an injection for a potential vaccine against COVID-19 at the Baragwanath Hospital on June 28, 2020 in Soweto, South Africa. The vaccine, developed by Oxford University's Jenner Institute, will inoculate 2,000 South Africans. Felix Dlangamandla/Beeld/Gallo Images via Getty Images
Vaccine efficacy measures how well a vaccine works at preventing disease among vaccinated people, when compared to unvaccinated individuals.
The vaccine efficacy numbers for coronavirus injections being reported from Pfizer, Moderna, and AstraZeneca are all preliminary, and based on their trials in tens of thousands of volunteers around the world.
